Why Annexon, Inc.’s (ANNX) Stock Is Up 5.04%
As of Thursday, July 30, Annexon, Inc.’s ANNX share price has surged by 5.04%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.23%
As of Thursday, July 16, Annexon, Inc.’s ANNX share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.22%
As of Friday, July 10, Annexon, Inc.’s ANNX share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Michael Rose
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.60%
As of Wednesday, July 08, Annexon, Inc.’s ANNX share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Annexon, Inc.’s (ANNX) Stock Is Up 5.59%
As of Monday, July 06, Annexon, Inc.’s ANNX share price has surged by 5.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $863.5 | $251.9 | 44% |
|
| Shares Out (Mil) | 194.2 | 50.8 | 76% |
|
| Institutional Ownership | 98.8% | 92.0% | 82% |
|
| Float (Mil) | 129.4 | 40.5 | 66% |
|
| Beta | 1.22 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 2,527 | 447 | 86% |
|
| Price Change (52-week) |
121.4% | 54.2% | 94% |
|
| Growth | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (26.7%) | (9.8%) | 16% |
|
| EPS (5yr) | 20.2% | 16.3% | 68 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (44.0%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.240) | ($0.979) | ($0.961) | |
| Month Ago EPS | ($0.240) | ($0.982) | ($0.923) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.302) | ($1.163) | ($0.956) | |
| Year/Year Chg | 5.7% | (27.2%) | (87.7%) | |
| Financials | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($197) | ($43) | 7% |
|
| EPS (TTM) | ($1.190) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($183) | ($30) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $78 | $3 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $22 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $733 | $182 | 38% |
|
| Valuation | ANNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.18 | 2.60 | 74% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (69.4%) | (49.7%) | 8% |
|
| ROE | (87.6%) | (55.4%) | 11% |
|
| Liabilities to Assets | 22.2% | 30.3% | 14% |
|
| F-Score | 2 | 3 | 7% |
|
Annexon, Inc. did not pass any screens on 7/30/2026.
